Market Overview

BlueBird Bio Unable To Rebound


BlueBird Bio Inc (NASDAQ: BLUE) shares are trading lower by $31 at $52.66 in Monday's session. The catalyst for the decline is mixed sickle cell data from it latest trial. The poor results prompted three different Wall Street firms to lower their ratings, while another lowered its price target.

After a lower open, it rallied to $63.89 before resuming its descent. It reached $51.72 and has rebounded into the $52 handle.

That takes the issue back into a thinly traded level from December 2014. In that month, it rallied from a low of $39.02 and ended the year at $91.72.

Posted-In: Premarekt outlookTechnicals Intraday Update Movers Trading Ideas


Related Articles (BLUE)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Credit Suisse's Top 10 Financial Stocks: Schwab Out, Goldman In

Amazon Still Benefiting From Its 'Loyalist' Head Start